---
title: Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea
nct_id: NCT01372956
overall_status: COMPLETED
sponsor: AstraZeneca
study_type: OBSERVATIONAL
primary_condition: Dyslipidemia
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01372956.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01372956"
ct_last_update_post_date: 2011-12-22
last_seen_at: "2026-05-12T07:08:40.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea

**Official Title:** Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)

**NCT ID:** [NCT01372956](https://clinicaltrials.gov/study/NCT01372956)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 4950
- **Lead Sponsor:** AstraZeneca
- **Conditions:** Dyslipidemia
- **Start Date:** 2011-08
- **Completion Date:** 2011-10
- **CT.gov Last Update:** 2011-12-22

## Brief Summary

This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients

## Detailed Description

MC MD

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient who has a dyslipidemia with a lipid profile result within 3 months
* Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.

Exclusion Criteria:

* Patient who involved in this study previously.
* Patient who participated in other clinical study with study drug within 90 days.
```

## Arms

- **Dyslipidemia**

## Primary Outcomes

- **Cholesterol goal attainment rate according to NCEP-ATP III guideline** _(time frame: Once, at enrollment)_

## Secondary Outcomes

- **Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.** _(time frame: Once, at enrollment)_
- **Cholesterol goal attainment rate related to CHD or disease history** _(time frame: Once, at enrollment)_

## Locations (20)

- Research Site, Busan, Busan, South Korea
- Research Site, Cheonan, Chungcheongnam-do, South Korea
- Research Site, Tae, Chungcheongnam-do, South Korea
- Research Site, Chuncheon, Gangwon-do, South Korea
- Research Site, Gwangju, Gwangju, South Korea
- Research Site, Anyang-si, Gyeonggi-do, South Korea
- Research Site, Bucheon-si, Gyeonggi-do, South Korea
- Research Site, Bundang, Gyeonggi-do, South Korea
- Research Site, Goyang-si, Gyeonggi-do, South Korea
- Research Site, Guri-si, Gyeonggi-do, South Korea
- Research Site, Uijeongbu-si, Gyeonggi-do, South Korea
- Research Site, Incheon, Incheon, South Korea
- Research Site, Gwangju, Jeollabuk-do, South Korea
- Research Site, Iksan, Jeollabuk-do, South Korea
- Research Site, Daegu, Kyeongsangbuk-do, South Korea
- Research Site, Deagu, Kyeongsangbuk-do, South Korea
- Research Site, Busan, Kyeongsangnam-do, South Korea
- Research Site, Changwon, Kyeongsangnam-do, South Korea
- Research Site, Cheongju-si, North Chungcheong, South Korea
- Research Site, Seoul, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.research site|busan|busan|south korea` — added _(2026-05-12)_
- `locations.research site|cheonan|chungcheongnam-do|south korea` — added _(2026-05-12)_
- `locations.research site|tae|chungcheongnam-do|south korea` — added _(2026-05-12)_
- `locations.research site|chuncheon|gangwon-do|south korea` — added _(2026-05-12)_
- `locations.research site|gwangju|gwangju|south korea` — added _(2026-05-12)_
- `locations.research site|anyang-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|bucheon-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|bundang|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|goyang-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|guri-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|uijeongbu-si|gyeonggi-do|south korea` — added _(2026-05-12)_
- `locations.research site|incheon|incheon|south korea` — added _(2026-05-12)_
- `locations.research site|gwangju|jeollabuk-do|south korea` — added _(2026-05-12)_
- `locations.research site|iksan|jeollabuk-do|south korea` — added _(2026-05-12)_
- `locations.research site|daegu|kyeongsangbuk-do|south korea` — added _(2026-05-12)_
- `locations.research site|deagu|kyeongsangbuk-do|south korea` — added _(2026-05-12)_
- `locations.research site|busan|kyeongsangnam-do|south korea` — added _(2026-05-12)_
- `locations.research site|changwon|kyeongsangnam-do|south korea` — added _(2026-05-12)_
- `locations.research site|cheongju-si|north chungcheong|south korea` — added _(2026-05-12)_
- `locations.research site|seoul|seoul|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01372956.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01372956*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*